Neurofibromatosis type 1 secondary prevention
|
Neurofibromatosis type 1 Microchapters |
|
Differentiating Neurofibromatosis type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neurofibromatosis type 1 secondary prevention On the Web |
|
American Roentgen Ray Society Images of Neurofibromatosis type 1 secondary prevention |
|
Risk calculators and risk factors for Neurofibromatosis type 1 secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.
Overview
Neurofibromatosis type 1 has a wide range of commorbidities, regular multidisciplinary follow-ups are mandatory. Annual mammogram and ophtalmologic examination should be made in patients with neurofibromatosis type 1. Neurocognitive evaluation and blood pressure measurements should be done regularly to record evolution and detect secondary causes of impairment.
Secondary Prevention
- Blood pressure should be measured routinely, including during childhood.Secondary causes of hypertension should be ruled out, including MEN 2B.[1]
- Complete ophtalmologic examination should be made annualy throughout adulthood or until 25 years of diagnosis to evaluate OPG. Slit lamp evaluation for Lisch nodules is made only once for confirmation of diagnosis.[1]
- Patients with neurofibromatosis type 1 should have regular DEXA scan follow-ups.[1]
- Neurocognitive evaluation should be done at a regular basis to test evolution.[1]
- Annual mammogram starting at age 30 should be made in patients with neurofibromatosis type 1 to screen breast cancer. Breast cancer should be managed agressively in these patients, considering bilateral mastectomy. [1]
- Calcium and vitamin D supplementation are rugularly prescribed to prevent osteoporosis and osteopenia.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Ly KI, Blakeley JO (November 2019). "The Diagnosis and Management of Neurofibromatosis Type 1". Med. Clin. North Am. 103 (6): 1035–1054. doi:10.1016/j.mcna.2019.07.004. PMID 31582003.
- ↑ Ly KI, Blakeley JO (November 2019). "The Diagnosis and Management of Neurofibromatosis Type 1". Med. Clin. North Am. 103 (6): 1035–1054. doi:10.1016/j.mcna.2019.07.004. PMID 31582003.